Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Covid

<< Previous

Bullboard Posts

Next >>

Comment by Amazighon Sep 09, 2021 5:26am

143 Views

Post# 33829896

RE:RE:Covid

Sacloco wrote: LOL...that's very funny Angela, what about the graft versus host disease drug that was gonna revolutionize the industry? Remember it performed better than expected in all three stages and then it was approved for the FDA fast track program? What happened to that?

Three stages? I had no idea we got past Phase II.
When did Phase III start, and where on earth did we get the $7 million to proceed with it?
Also, when the heck did we get assigned a Fast Track designation from the FDA, because as far as I know, as of December 2019 we still hadn’t applied for it. So when was it given to us?

The rest of your post is just the usual uninformed troll garbage.
Heck, you couldn’t even get the simple basics of research right.

<< Previous

Bullboard Posts

Next >>

Cizzle Brands, Changing Consumer Habits in Consumables